PerkinElmer Announces Agreement with Predictive Diagnostics That Allows for Comprehensive Biomarker Platform.BOSTON -- New Biomarker Platform Critical In Accelerating Drug Development PerkinElmer Inc. (NYSE NYSE See: New York Stock Exchange : PKI (Public Key Infrastructure) A framework for creating a secure method for exchanging information based on public key cryptography. The foundation of a PKI is the certificate authority (CA), which issues digital certificates that authenticate the identity of ), a leading provider of drug discovery, life science research, and analytical solutions and Predictive Diagnostics, Inc. (PDI PDI Protein Disulfide Isomerase PDI Personal Docente e Investigador (Spanish: Personal Educational and Investigating) PDI Pre Delivery Inspection PDI Professional Development Institute ), a leading clinical proteomics company and wholly owned subsidiary Wholly Owned Subsidiary A subsidiary whose parent company owns 100% of its common stock. Notes: In other words, the parent company owns the company outright and there are no minority owners. of Large Scale Biology Corporation (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on : LSBC LSBC Law Society of British Columbia LSBC Large Scale Biology Corporation LSBC Lone Star Bulldog Club LSBC Lasalle & Bureau County Railroad Company LSBC Lifesaver for Babies and Children (St John Ambulance, UK) LSBC Lone Star Bit Company ), today announced they have entered into a collaborative partnership for advanced biomarker discovery Biomarker discovery is the process by which biomarkers are discovered. It is a medical term. Many commonly used blood tests in medicine are biomarkers. The way that these tests have been found can be seen as biomarker discovery. technology to accelerate drug development and diagnostic testing Diagnostic testing Testing performed to determine if someone is affected with a particular disease. Mentioned in: Von Willebrand Disease . Under the terms of the agreement, PerkinElmer will provide access to PDI's proprietary Biomarker Amplification Filter (BAMF bamf - /bamf/ 1. [Old X-Men comics] Notional sound made by a person or object teleporting in or out of the hearer's vicinity. Often used in virtual reality (especially MUD) electronic fora when a character wishes to make a dramatic entrance or exit. 2. (TM)) Technology customized for PerkinElmer's prOTOF(TM) 2000 MALDI MALDI Matrix-Assisted Laser Desorption/Ionization O-TOF mass spectrometer to create the "industry standard" platform for biomarker discovery and analysis. PerkinElmer's Life and Analytical Sciences sales and marketing team will exclusively offer PDI's BAMF Technology services to leading pharmaceutical companies and major research institutions. PDI's BAMF(TM) Technology is a comprehensive suite of in silico machine learning technologies and advanced informatics tools that use a simple blood test for the discovery of biomarker fingerprints to diagnose diseases utilizing high-resolution mass spectrometry mass spectrometry or mass spectroscopy Analytic technique by which chemical substances are identified by sorting gaseous ions by mass using electric and magnetic fields. data. PDI has developed its BAMF Technology for use in serum-based tests for early diagnosis of cancer and other life-threatening diseases. "Predictive Diagnostics is a recognized leader in biomarker analysis software. Their proprietary set of algorithms and informatics capabilities will complement our mass spectrometry and proprietary consumables offerings and complete our total solution for biomarker discovery and screening." said Peter Coggins, Ph.D., president of PerkinElmer Life and Analytical Sciences. "We believe this solution will be enabling technology for our pharmaceutical, biotech, and academic customers in the proteomic biomarker field." PerkinElmer's prOTOF 2000 is part of the company's High Content Proteomics solution, a comprehensive approach to proteomics research pioneered by PerkinElmer. Using advanced, innovative technologies, like the prOTOF(TM) 2000 MALDI O-TOF, PerkinElmer has developed a suite of tools that achieve maximum meaningful data from any sample, improving results and reproducibility. "PerkinElmer is the leader in state-of-the-art proteomic hardware and advanced purification solutions needed for advanced proteomic biomarker analysis," said Kevin Ryan, CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of Predictive Diagnostics. "We are confident that the combined strength of PerkinElmer's proteomic hardware and PDI's portfolio of discovery and diagnostic solutions will add significant value to our pharmaceutical and life sciences customers." Further details about PerkinElmer's prOTOF(TM) 2000 mass spectrometer and its uses of BAMF Technology will be presented today by Dr. Gershon M. Wolfe and Dr. Guy della Cioppa of PDI at the Cambridge Healthtech Institute's Protein Biomarker 2004 Conference in Philadelphia. For information on the conference or PerkinElmer's proteomic offering please contact Dr. Mary Lopez of PerkinElmer 1-617-834-1862. (www.healthtech.com/2004/bmk/day2.asp). About PerkinElmer PerkinElmer, Inc. is a global technology leader focused in the following businesses - Life and Analytical Sciences, Optoelectronics and Fluid Sciences. Combining operational excellence and technology expertise with an intimate understanding of our customers' needs, PerkinElmer provides products and services in health sciences and other advanced technology markets that require innovation, precision and reliability. The Company serves customers in more than 125 countries, and is a component of the S&P 500 Index. Additional information is available through www.perkinelmer.com or 1-877-PKI-NYSE. About Large Scale Biology Corporation Large Scale Biology uses its biomanufacturing, functional genomics and proteomics technologies to develop and manufacture drugs, vaccines and diagnostics for effective treatment of disease. Corporate offices, Predictive Diagnostics, Inc. (www.predictivediagnostics.com), and Biopharmaceutical Development laboratories are headquartered in Vacaville, California, and the Company's commercial-scale biomanufacturing facility is located in Owensboro, Kentucky. For more information about Large Scale Biology Corporation, visit the Company's website at www.lsbc.com. LSBC(R) and BAMF(TM) are trademarks of Large Scale Biology Corporation. prOTOF is a trademark of MDS MDS, n See temporomandibular pain-dysfunction syndrome. MDS 1 Maternal deprivation syndrome, see there 2 Myelodysplastic syndrome, see there Sciex. All other trademarks are the property of PerkinElmer, Inc. Factors Affecting Future Performance This press release contains "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. Any statements contained in this press release that relate to prospective events or developments are deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "projects," "forecasts," "will" and similar expressions are intended to identify forward-looking statements. There are a number of important risk factors that could cause actual results or events to differ materially from those indicated by these forward-looking statements, including risks related to cyclical downturns affecting several of the industries into which we sell our products, our failure to introduce new products in a timely manner, the impact of our debt on our cash flow and investment opportunities, our ability to comply with financial covenants contained in our credit agreements and debt instruments, risks related to our international operations, our ability to adjust our operations to address unexpected changes, our ability to execute acquisitions and license technologies and successfully integrate acquired businesses and licensed technologies into our existing business, the loss of any of our licenses that may require us to stop selling products or lose competitive advantage, competition, regulatory changes, our failure to obtain and enforce intellectual property protection, our defense of third party claims of patent infringement patent infringement n. the manufacture and/or use of an invention or improvement for which someone else owns a patent issued by the government, without obtaining permission of the owner of the patent by contract, license or waiver. and our ability to realize the full value of our intangible assets, as well as other factors which we describe under the caption "Forward-Looking Information and Factors Affecting Future Performance" in our most recently filed annual report on Form 10-K Form 10-K A report required by the SEC from exchange-listed companies that provides for annual disclosure of certain financial information. Form 10-K See 10-K. and in our most recently filed quarterly report on Form 10-Q Form 10-Q See 10-Q. . We disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release. PerkinElmer, Inc. is a global technology leader focused in the following businesses - Life and Analytical Sciences, Optoelectronics and Fluid Sciences. Combining operational excellence and technology expertise with an intimate understanding of our customers' needs, PerkinElmer provides products and services in health sciences and other advanced technology markets that require innovation, precision and reliability. The Company serves customers in more than 125 countries, and is a component of the S&P 500 Index. Additional information is available through www.perkinelmer.com or 1-877-PKI-NYSE. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion